This conotoxin was on trial to cure myocardial infarction. (7−12) Only one conotoxin, namely, κ-PVIIA, was in the preclinical phase to treat non-neurological complaints. (2,6) The χ-MrIA, ω-CVID, contulakin-G, α-Vc1.1, and μO-MrVIB conotoxins were in preclinical and clinical trials to cure neuropathic pain or neuroprotection. Food and Drug Administration in 2004 to treat chronic pain. The ω-MVIIA conotoxin, marketed as ziconitide, was approved by the U.S. (1,4,5) Neurologic application for pain reduction is the most common ongoing approved, preclinical, or clinical trial of conotoxins or their derivates. (3) Unique potency and selectivity profiles for a range of neuronal targets have made several conotoxins valuable as drug leads of analgesics, neuropsychiatric, and other neuropharmacologicals. The snails capture prey using a diverse array of toxins, mainly neurotoxins, (2) although a few can be cardioactive. (1) Many conotoxins have been identified to have neuronal targets. Conotoxins are natural peptide components of the venoms of marine cone snails of the Conus genus, which are remarkably diverse in terms of structure and function.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |